ASAH1 and glioblastoma: Based on the lack of FDA-approved sphingosine kinase inhibitors for GBM and the finding that ASAH1 is increased following radiotherapy, we chose to focus on ASAH1, an enzyme responsible for producing sphingosine and regulating ceramide catabolism [4,63].